US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
CS

CSCIFStockCOSCIENS Biopharma Inc.

Healthcare · CA

$6.49 last close 2026-10-16
Open in terminalCompare
Alert

Verdicts genuinely change. Free email alert the moment CSCIF's does — no target price to set, unlike "Alert" above.

Sharia status
NOT YET SCREENED
Not screened yet — no methodology has been established for this symbol

Methodology breakdown computing — it will appear here on its own.

🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No active setup right now. The technical picture doesn't show a clear edge — check back when the trend or momentum shifts.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure0 of 2 timeframes bullish · 9.1% aligned
VWAPPrice holding above VWAP ($6.26)
Momentum10-day rate of change +18.4%
Market & analysts

Still fetching analyst coverage — it ran past this page's budget, so the page painted without waiting. The fetch is still running; reload in a moment and it will be here.

Momentum (10d)
+18.4%
rate of change
SMC grade
F · 29
9.1% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
F · 29
SMC grade — 9.1% timeframe alignment
+18.4%
Rate of change (10d)

🕌 In-house Compliance Research

Computing the full ratio and business-activity breakdown for CSCIF — this runs off the critical path so the page paints first. It will appear here on its own.

7.005.453.902.340.792025-10-172026-04-202026-10-16

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance

Not enough completed daily bars to compute pivots.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
4.77 – 5.19
±4.29% from 4.98, made 2026-09-10 · resolves 2026-09-17
SELL
from 19 indicators
61.9% of our last 5789 forecasts landed inside their stated range, and 49.9% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG BUY
19 indicators
OscillatorsSTRONG BUY
2 buy · 4 neutral · 1 sell
Moving averagesSTRONG BUY
11 buy · 0 neutral · 1 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)61.30NEUTRAL
Stochastic %K (14)42.11NEUTRAL
CCI (20)40.46NEUTRAL
Williams %R (14)-57.89NEUTRAL
MACD (12,26,9)-0.05SELL
ROC (10)0.78BUY
Momentum (10)0.05BUY
EMA (10)6.42BUY
SMA (10)6.51SELL
EMA (20)6.25BUY
SMA (20)6.27BUY
EMA (30)6.06BUY
SMA (30)5.95BUY
EMA (50)5.70BUY
SMA (50)5.68BUY
EMA (100)4.89BUY
SMA (100)4.69BUY
EMA (200)3.73BUY
SMA (200)3.26BUY

About COSCIENS Biopharma Inc.

Healthcare · Biotechnology

COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. In addition, it focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.

cosciensbio.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

No real edge — avoid

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily NEUTRAL 19
⏲ 5-Min BEARISH 19

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

+18.4%
Rate of change (10d)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Still fetching insider filings — it ran past this page's budget, so the page painted without waiting. The fetch is still running; reload in a moment and it will be here.

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-10-13 · Asset managers net 915835 (+9220)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.

Tell us what's working, what's confusing, or what you want to see next — read by a real person, not a form that goes nowhere.